<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01942200</url>
  </required_header>
  <id_info>
    <org_study_id>ONKOOXA01</org_study_id>
    <nct_id>NCT01942200</nct_id>
  </id_info>
  <brief_title>A Non Interventional Study With Oxaliplatin Onkovis (Oxaliplatin) Utilized for the Treatment of Cancer</brief_title>
  <official_title>Open, Multicenter Observational Study of Oxaliplatin Utilized in Combination Therapy for Adjuvant Treatment of Colon Carcinoma of Stage III After Complete Removal of the Primary Tumor and for Treatment of Metastasizing Colorectal Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Onkovis GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AKP Freiburg GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Onkovis GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this observational study with Oxaliplatin onkovis is to determine the
      number of treatment cycles and the quantity of Oxaliplatin onkovis needed for this purpose
      under the special circumstances of ambulant chemotherapy.

      Onkovis aims to contribute to an economical utilization of the chemotherapeutics. This
      includes provision of appropriate packaging sizes to decrease the excess quantity to be
      discarded, and thus also follows this objective.

      Secondary objective is the assessment of the side effects of Oxaliplatin onkovis. To this
      end, data regarding co-medication and adverse events are also collected.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2013</start_date>
  <completion_date type="Actual">July 25, 2018</completion_date>
  <primary_completion_date type="Actual">July 25, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The Quantity of Oxaliplatin onkovis needed per treatment cycle</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Determine the quantity of Oxaliplatin onkovis needed per treatment cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events during and after treatment</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>The number and type of adverse events during and after the intra-venous application of Oxaliplatin will be assessed and documented.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">383</enrollment>
  <condition>Carcinoma</condition>
  <arm_group>
    <arm_group_label>Carcinoma, Oxaliplatin onkovis (Oxaliplatin)</arm_group_label>
    <description>Treatment in combination therapy for adjuvant treatment of colon carcinoma of stage III (Dukes C) after complete removal of the primary tumor, as well as for treatment of metastasizing colorectal carcinoma.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated in practices, clinics, hospitals
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication for Oxaliplatin according to the Summary of Product Characteristics (SmPC)
             and treating physician

        Exclusion Criteria:

          -  According to the Oxaliplatin SmPC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Practice</name>
      <address>
        <city>Elstra</city>
        <zip>01920</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice</name>
      <address>
        <city>Leipzig</city>
        <zip>04277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice</name>
      <address>
        <city>Naunhof</city>
        <zip>04683</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>September 10, 2013</study_first_submitted>
  <study_first_submitted_qc>September 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2013</study_first_posted>
  <last_update_submitted>August 6, 2018</last_update_submitted>
  <last_update_submitted_qc>August 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>carcinoma</keyword>
  <keyword>colon cancer</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>ambulant chemotherapy</keyword>
  <keyword>treatment cycles</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Oxaliplatin onkovis</keyword>
  <keyword>Quantity of Oxaliplatin</keyword>
  <keyword>Packaging Sizes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

